The decision guide

Is HRT right for me?

It’s the most-asked question in every menopause conversation, and the one you can never seem to get a straight answer to. This is how to think it through, in plain language, before you ever sit down with us.

Walk me through it Talk it through with us

This guide is for general education, not medical advice, and it doesn’t replace a personal evaluation.

Start here

You’re not behind. And it’s not a dumb question.

“Am I even a candidate?” “Is it too late?” “What do my labs mean?” These are the questions thousands of women ask into the void every day and get silence, or a shrug, in return. They deserve real answers. Here are the five that matter most, and how a specialist actually thinks about each one.

What 2002 actually got wrong

The scare that talked a generation out of treatment

If you were told years ago that hormone therapy was dangerous, that message almost certainly traces back to a single moment. When the Women’s Health Initiative, the big landmark trial, published in 2002, the reaction was immediate and enormous: HRT prescriptions fell by roughly half within a year.1 Overnight, a treatment women had relied on became something to fear.

Here’s what almost no one was told afterward. Later reappraisals of that same trial concluded the original interpretation had overstated the absolute risks, especially for younger women near the start of menopause.1 Part of the reason is who was actually studied: the trial skewed older, with only about 1 in 8 participants aged 50–54.1 In other words, a study done largely in women well past menopause was used to set the rules for women just entering it. The headline traveled the world in a week; the correction took twenty years and never really caught up.

The timing that changes everything

When you start matters as much as whether you start

The most important thing the old headlines flattened is this: the benefits and risks of hormone therapy depend heavily on your age and how close you are to menopause. Researchers call it the “timing hypothesis,” and it’s the piece that turns a scary blanket answer back into a real, individual one. The body of a woman in her early fifties, freshly through the transition, is not in the same place as a body two decades further on, and hormones behave differently depending on which one you’re treating.

That’s why the reflexive “no” a whole generation of women received was never really an answer. It was a misread of a trial done mostly in older women, applied without discrimination to everyone.1 A good evaluation doesn’t start from that blanket no. It starts from where you are (your age, your timeline, your symptoms), because for hormone therapy, timing isn’t a footnote. It’s close to the whole question.

What HRT can actually do

This was never only about hot flashes

Most conversations about HRT stop at symptom relief: the night sweats, the flashes, the sleep. Those matter. But estrogen does quieter, deeper work in the body, and understanding it is what turns “should I bother?” into a real question worth asking.

Your heart

Estrogen is cardioprotective: it helps keep blood vessels flexible and your cholesterol and clotting in a healthier balance. As it declines through menopause, cardiovascular risk climbs. This isn’t a minor line item: heart disease is the number one killer of women, causing about 1 in 3 female deaths, far ahead of any cancer.23 The reason that surprises so many women is that we were all taught to fear breast cancer most, while the bigger threat was building quietly in the background.

Your brain

Estrogen also helps power memory-critical regions of the brain. Research links earlier menopause to faster cognitive decline and higher levels of tau, a protein that marks Alzheimer’s disease, and finds those associations were weaker in women who took hormone therapy.45 That is genuinely hopeful, and it deserves an honest asterisk: the evidence on HRT and the brain is still mixed and timing-dependent, and no responsible clinic will promise you it prevents dementia. What the science supports is that this is a real area of protection worth discussing: not a guarantee, and not something to dismiss.

The cost of the scare

Avoiding treatment was never “the safe choice”

We tend to imagine that saying no to a medication is automatically the cautious, risk-free option. When it comes to estrogen after 2002, that instinct may have carried a real cost. One analysis (Sarrel and colleagues, 2013) estimated that between roughly 19,000 and 91,000 U.S. women (specifically those who’d had a hysterectomy, aged 50–59) may have died prematurely over a decade from avoiding estrogen after the scare.6

Read that number carefully, because it’s easy to misuse. It is a modeled estimate with a wide range, for one specific subgroup of women: not a body count, and not a settled fact. The honest way to hold it is exactly as written: one analysis estimated between 19,000 and 91,000. Even taken cautiously, though, it makes the essential point. There is no truly “neutral” option here. Both taking hormones and avoiding them carry consequences, which is precisely why the decision deserves a real conversation instead of a reflex in either direction.

So how do we decide?

Not a yes for everyone: an honest yes-or-no for you

If you’ve read this far hoping for a verdict, here’s the truthful one: there isn’t a universal answer, and anyone who gives you a blanket yes is being as careless as the blanket no you were probably handed years ago. Hormone therapy is right for some women and not for others, and the only way to know which you are is to actually look.

That means a real risk-and-benefit conversation built around your history, your symptoms, and what you’re trying to protect for the decades ahead: your heart, your brain, your bones, your quality of life. It weighs what you’d gain against what you’d risk, in the context of your own age and timing, not a headline’s. You don’t have to arrive with the answer. You just have to be looked at honestly, by someone who knows this well enough to think it through with you. That’s what a first visit is for.

  1. Hormone Replacement Therapy After the WHI: Clinician’s Evidence Timeline, 2002–2025: ~50% prescription drop; overstated risks; older-skewed trial population (~1 in 8 aged 50–54)
  2. Menopause Transition and Cardiovascular Disease Risk: AHA Scientific Statement, Circulation (estrogen decline & rising cardiovascular risk)
  3. Cardiovascular disease as the leading cause of death in women: about 1 in 3 female deaths (CDC data via AHA, PMC)
  4. Estrogen, menopause, and Alzheimer’s disease: neuroprotection hypothesis (PMC)
  5. Age at menopause, synaptic integrity, and Alzheimer’s risk: earlier menopause linked to faster decline and higher tau, attenuated in women who took hormone therapy (Science Advances)
  6. Sarrel et al. (2013), The Mortality Toll of Estrogen Avoidance: modeled estimate of ~19,000–91,000 excess deaths over a decade among hysterectomized women aged 50–59 (American Journal of Public Health)
Free · straight to your inbox

Get the “Is HRT Right for Me?” guide.

The printable companion: the five questions, plus the exact things to ask so you’re never dismissed or rushed again. Tell us where to send it:

Cover of the Is HRT Right for Me? decision guide
  • ✓The five questions that decide it, and how a specialist weighs each
  • ✓The “is it too late?” question, answered honestly
  • ✓The exact questions to bring to your appointment

Send me the guide

A private PDF, straight to your inbox. No spam. Unsubscribe anytime. Or download it now →

Common questions

Hormone therapy, answered.

There is no blanket answer, and that is the honest one. The benefits and risks of hormone therapy depend heavily on your age, how close you are to menopause, and your personal health history. Much of the fear around HRT traces back to a 2002 study whose findings were later reappraised as overstated for younger women. The real question is not "is it safe for everyone" but "is it right for you."
Not automatically. Timing matters: researchers call it the timing hypothesis, and the body of a woman freshly through the transition responds differently than one decades past it. That does not mean a hard cutoff; it means your age and distance from menopause are part of an individual evaluation, not a reason for a reflexive no. Talk with a menopause specialist before assuming the window has closed.
Candidacy is decided by looking at the whole of you: your symptoms, your age and timing, your medical and family history, and what you want to protect for the decades ahead. Hormone therapy is right for some women and not for others, and the only way to know which you are is a real risk-and-benefit conversation, not a checklist or a headline.
In 2002, a single large trial, the Women's Health Initiative, triggered headlines that made hormone therapy something to fear almost overnight. Later reappraisals concluded the original interpretation overstated the risks, especially for younger women near the start of menopause, partly because the trial skewed toward older participants. The headline traveled fast; the correction took decades and never fully caught up.
Symptom relief is only part of the story. Estrogen also does quieter work in the body: it helps keep blood vessels flexible, supports memory-critical regions of the brain, and is tied to the strength of your bones. That is why the HRT conversation is really about what you want to protect for the decades ahead, not just about cooling the flashes.
Timing is close to the whole question. The research known as the timing hypothesis suggests the benefits and risks look different depending on your age and how near you are to menopause, which is why starting the conversation earlier tends to give you more options. If you are in or approaching the transition, that is a good moment to get evaluated.
A thoughtful evaluation usually starts with your story: your symptoms, your cycle history, and your health background. Labs can add useful context, though numbers alone never decide the answer. If you have been handed results with no explanation, bring them along; a menopause specialist can translate what they mean for you, and just as importantly, what they cannot.
Perimenopause, the years of hormonal swings before your final period, is often when symptoms first bite, and it is a legitimate time to seek help. You do not have to wait for your periods to stop to have the conversation. An evaluation looks at where you are in the transition and what fits your body now, not a one-size-fits-all rule.
A blanket no is not the same as an individual answer. A whole generation of women received a reflexive no built on a misread of one trial done mostly in older women. If your no came without a real look at your age, timing, symptoms, and history, it deserves a second opinion from someone who treats menopause every day.
You do not have to decide alone, and you do not need the answer before you walk in. The decision comes from an honest risk-and-benefit conversation built around your history, your symptoms, and your goals. That is exactly what a first visit at Mariposa is for; you can book a consultation and think it through with a specialist.

Still not sure? That’s exactly what the first conversation is for.

You don’t have to have it figured out before you come in. Bring the questions. We’ll bring the answers.

Book a Consultation